248 related articles for article (PubMed ID: 23731241)
1. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
[TBL] [Abstract][Full Text] [Related]
2. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).
Chan EC; Koh PK; Mal M; Cheah PY; Eu KW; Backshall A; Cavill R; Nicholson JK; Keun HC
J Proteome Res; 2009 Jan; 8(1):352-61. PubMed ID: 19063642
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
5. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
6. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
[TBL] [Abstract][Full Text] [Related]
7. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
10. ¹H NMR-based metabolic profiling of human rectal cancer tissue.
Wang H; Wang L; Zhang H; Deng P; Chen J; Zhou B; Hu J; Zou J; Lu W; Xiang P; Wu T; Shao X; Li Y; Zhou Z; Zhao YL
Mol Cancer; 2013 Oct; 12(1):121. PubMed ID: 24138801
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
12. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer.
Gu H; Pan Z; Xi B; Asiago V; Musselman B; Raftery D
Anal Chim Acta; 2011 Feb; 686(1-2):57-63. PubMed ID: 21237308
[TBL] [Abstract][Full Text] [Related]
13. Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies.
Mirnezami R; Jiménez B; Li JV; Kinross JM; Veselkov K; Goldin RD; Holmes E; Nicholson JK; Darzi A
Ann Surg; 2014 Jun; 259(6):1138-49. PubMed ID: 23860197
[TBL] [Abstract][Full Text] [Related]
14. Grading of endometrial cancer using
Skorupa A; Poński M; Ciszek M; Cichoń B; Klimek M; Witek A; Pakuło S; Boguszewicz Ł; Sokół M
Sci Rep; 2021 Sep; 11(1):18160. PubMed ID: 34518615
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
16. Discrimination of Basal Cell Carcinoma from Normal Skin Tissue Using High-Resolution Magic Angle Spinning 1H NMR Spectroscopy.
Mun JH; Lee H; Yoon D; Kim BS; Kim MB; Kim S
PLoS One; 2016; 11(3):e0150328. PubMed ID: 26934749
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics for Age Discrimination of Ginseng Using a Multiplex Approach to HR-MAS NMR Spectroscopy, UPLC-QTOF/MS, and GC × GC-TOF/MS.
Yoon D; Choi BR; Ma S; Lee JW; Jo IH; Lee YS; Kim GS; Kim S; Lee DY
Molecules; 2019 Jun; 24(13):. PubMed ID: 31252608
[TBL] [Abstract][Full Text] [Related]
18. Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors.
Wang H; Hu D; Yao H; Chen M; Li S; Chen H; Luo J; Feng Y; Guo Y
Eur Radiol; 2019 Nov; 29(11):6182-6190. PubMed ID: 31016445
[TBL] [Abstract][Full Text] [Related]
19. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
